Company

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry's Largest Deal of Its Kind
BiosimilarsFRA: FMEA

Fresenius Medical Care Inks Decade‑Long Biosimilar Partnership with WuXi Biologics – Rights to Up to 37 Candidates in Industry’s Largest Deal of Its Kind

Fresenius Medical Care (FRA: FMEA) announced a development partnership with WuXi Biologics (HKG: 2269) securing rights to up to 37 new biosimilar candidate products over the next decade. The collaboration…

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes

CSPC Reports Positive Top‑Line Phase III Data for Prusogliptin/Dapagliflozin/Metformin Triple Combination – Superior Glycemic Control in Type 2 Diabetes

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Brise Pharmaceuticals Reports Milestone Progress on AbbVie Licensing Deal – Up to $757 Million for Two Preclinical Migraine Candidates

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Clinical trial resultsHenlius Biotech

Shanghai Henlius Biotech’s HLX04-O Meets Primary Endpoints in Phase III Trial for Wet AMD, Demonstrating Non-Inferiority to Ranibizumab

RNAi / ASO

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors
CancerCell-therapy

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

ASX: DXBDimerix

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Show More